Erratum: A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study (Gynecol Oncol 127 (2012) (538-543))

Robert L. Coleman, Michael W. Sill, Heather A. Lankes, Amanda Nickles Fader, Neil J. Finkler, James S. Hoffman, Peter G. Rose, Gregory P. Sutton, Charles W. Drescher, D. Scott McMeekin, Wei Hu, Michael Deavers, Andrew K. Godwin, R. Katherine Alpaugh, Anil K. Sood

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)252-253
Number of pages2
JournalGynecologic oncology
Volume130
Issue number1
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Coleman, R. L., Sill, M. W., Lankes, H. A., Fader, A. N., Finkler, N. J., Hoffman, J. S., Rose, P. G., Sutton, G. P., Drescher, C. W., McMeekin, D. S., Hu, W., Deavers, M., Godwin, A. K., Alpaugh, R. K., & Sood, A. K. (2013). Erratum: A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study (Gynecol Oncol 127 (2012) (538-543)). Gynecologic oncology, 130(1), 252-253. https://doi.org/10.1016/j.ygyno.2013.04.007